Richard Bihrle

Indiana University School of Medicine

Medicine · Health Sciences

44h-index5.9kcitations239works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Testicular diseases and treatments(89), Bladder and Urothelial Cancer Treatments(70), Urological Disorders and Treatments(45), Urinary and Genital Oncology Studies(42), Urologic and reproductive health conditions(40)

Publications237 total

Long-term Renal Preservation and Complication Profile With Ileal Ureter Creation
Urology·2024· 3 cited
Ileal Ureter Utilization in Patients With Previous Urinary Diversions
Urology·2023· 2 cited
Supplementary Figure Legend from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S1 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Data from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Figure Legend from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S1 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S3 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Data from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S2 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S3 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S2 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Early and Midterm Complications of the Continent Catheterizable Indiana Pouch Urinary Diversion: A 7-year Experience
Urology·2022· 3 citedOpen Access
AUTHOR REPLY
Urology·2021
Longitudinal Health Related Quality of Life After Open Radical Cystectomy: Comparison of Ileal Conduit, Indiana Pouch, and Orthotopic Neobladder
Urology·2021· 14 cited
Surgical Management of Retrocrural Disease in Germ Cell Tumors: Outcomes and Evolution of Practice
The Journal of Urology·2020· 4 cited
Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institution
Scandinavian Journal of Urology·2020· 16 citedOpen Access
MP49-18 EARLY COMPLICATIONS AS A RESULT OF INDIANA POUCH URINARY DIVERSION: A 7 YEAR EXPERIENCE
The Journal of Urology·2020Open Access
Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?
Urologic Oncology Seminars and Original Investigations·2020· 4 cited
Robotic and open partial nephrectomy for tumors in a solitary kidney
Journal of Clinical Urology·2020· 11 cited
page 1 of 12Next →

Frequent Co-authors

Richard S. Foster(41), John P. Donohue(27), Michael O. Koch(15), Randall G. Rowland(14), Lawrence H. Einhorn(10), Stephen D.W. Beck(9), Thomas A. Gardner(6), Narendra T. Sanghvi(5), M. Francesca Monn(5), Timothy A. Masterson(5), Gregory R. Wahle(5), Ashraf Mosharafa(4), Hristos Z. Kaimakliotis(4), Jose A. Pedrosa(4), K. Clint Cary(4), Thomas M. Ulbright(4), Christopher L. Coogan(3), F. J. Fry(3), Liang Cheng(3), Ilan Leibovitch(3)